Eiger BioPharmaceuticals, Inc.
EIGR
Rankning i aktier
#36451
Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company... Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and bringing to market targeted therapies for rare and ultra-rare diseases across the United States and internationally. Its primary investigational drug, Lonafarnib, an orally administered small molecule, is currently undergoing Phase III clinical trials for the treatment of hepatitis delta virus (HDV) infection. Other promising candidates in its portfolio include Lambda, which has completed Phase II clinical trials and is designed to target type III interferon receptors; Lonafarnib, also being evaluated for progeria and progeroid laminopathies; and Avexitide, an agent for congenital hyperinsulinism that has also successfully concluded Phase II studies for post-bariatric hypoglycemia. Established in 2008, Eiger BioPharmaceuticals, Inc. maintains its headquarters in Palo Alto, California.
Aktiekurs
$1.73
Senast synkroniserad: 2025-06-17
Marknadsvärde
$2.55M
Förändring (1 dag)
-0.29%
Förändring (1 år)
-79.71%
Land
US
Handel Eiger BioPharmaceuticals, Inc. (EIGR)
Kategori
Healthcare
P/B-tal för Eiger BioPharmaceuticals, Inc. (EIGR)
P/B-tal per October 2026 TTM: -0.87
Enligt Eiger BioPharmaceuticals, Inc. senaste finansiella rapporter och aktiekurs är det aktuella P/B-talet (TTM) -0.87. I slutet av 2022 hade företaget ett P/B-tal på 0.89.
Historik för P/B-tal för Eiger BioPharmaceuticals, Inc. från 2016 till 2026
P/B-tal vid årets slut
| År | P/B-tal | Ändra |
|---|---|---|
| 2026 (TTM) | -0.87 | 20.54% |
| 2023 | -0.72 | -181.06% |
| 2022 | 0.89 | -63.50% |
| 2021 | 2.43 | -33.14% |
| 2020 | 3.64 | -39.45% |
| 2019 | 6.01 | 187.35% |
| 2018 | 2.09 | -61.30% |
| 2017 | 5.41 | 214.56% |
| 2016 | 1.72 | 0.00% |
P/B-tal för liknande företag eller konkurrenter
| Företag | P/B-tal | Skillnad i P/B-tal | Land |
|---|---|---|---|
| 6.251 | -820.24% |
US
|
|
| 13.2547 | -1,627.22% |
US
|
|
| 4.208 | -584.85% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | -812.34% |
NL
|
